Pulmonary hypertension Phase II progress for Novartis and Bayer Schering
This article was originally published in Scrip
Executive Summary
Positive preliminary Phase II findings for two novel pulmonary hypertension (PH) treatments, Bayer Schering Pharma'sfirst-in-class vasodilator riociguat (BAY 63-2521) and Novartis's oncology drug Glivec (imatinib) were presented at the recent European Respiratory Society congress in Berlin, Germany.